News

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses basal cell carcinoma and Mohs surgery related to Jill Biden's most recent skin cancer diagnosis.

Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are popular for the month of February.

Today is Rare Disease Day. The Food and Drug Administration (FDA) defined a rare disease as a condition affecting less than 200,000 people in the United States.

Learn more about what in-depth topics were covered in the February 2023 issue of Dermatology Times®.

The autoinflammatory condition is associated with mutations in the NOD2 gene and usually affects children younger than 4 years.

VP-102 could be the first FDA-approved treatment for molluscum contagiosum.

Nivolumab for completely resected stage IIB or IIC melanoma is also validated by the European Medicines Agency.

Researchers have linked the neurodegenerative disorder to several autoimmune diseases, including the rare skin condition bullous pemphigoid.

Researchers from Crown Laboratories say new treatment has shown improvements in skin concerns such as texture, wrinkles and sun damage.

Click here to answer this week's poll.

Researchers found that apremilast could reduce alcohol intake by more than half per day, on average.

ICYMI, this week we had stories about hidradenitis suppurativa coverage at Winter Clinical Miami, an NDA submission for roflumilast foam, an overview of the 2023 Biosimilars Report from Cardinal Health, and more.

In this week’s Pointers with Dr Portela, the 208SkinDoc shows how to find an ideal and affordable acne skin care routine.

Study participants saw a rapid decrease in inflammatory lesions with the once-daily antibiotic, antibacterial, and retinoid gel.

This week's edition of the Mainstream Patient features stories about treating dry eyelids, face masks for acne-prone skin, acne scar treatments, and more.

A lawsuit, filed by 28 plaintiffs in California, seeks a collective $75,000 in damages.

Researchers link proximity to heavy traffic and risk of atopic dermatitis in new study.

Look back at 10 of the innovative sessions presented at the 2023 Winter Clinical Hawaii Conference in Kohala Coast, Hawaii.

Patients suffering from atopic dermatitis may suffer more during the cold, dry winter month. Bernard Cohen, MD, professor of pediatrics and dermatology at Johns Hopkins University School of Medicine in Baltimore, Maryland, explores various treatment options that will add moisture back into the skin during seasonal flare-ups.

The drug used to treat several dermatological disorders has immunosuppressive effects and has been linked with photosensitizing properties.

Biosimilars have been a trending topic in 2023 with 8 adalimumab biosimilars expected to hit the market this year.

Will Kirby, DO, FAOCD, talks with Blossom Hashemi, MSN, BS, FNP-C, about the best aesthetic career advice, available resources, and the role of allied health care professionals in aesthetics.

Clinicians should strive to address the unique medical and aesthetic challenges seen in vitiligo.

Adolescents and adults with seborrheic dermatitis may have a new topical treatment soon.

Recent research highlighted the important role of the skin’s microbiota in maintaining the homeostasis of the skin and the potential role the human microbiota may play in the development of skin cancer.

It’s crucial for patients and health care providers to consider their personal wellbeing in their daily lives.

Research published in JAMA Dermatology finds dupilumab works quickly and safely for patients with erythrodermic atopic dermatitis.

From topical antibiotics like clindamycin to biologic injectables like adalimumab to surgical options like deroofing, treatment for HS can come in many forms.

Emmy Graber, MD, MBA, covered it all in her Winter Clinical Miami talk, offering take-home pearls via patient case studies.

With now more than 6 months of real-world use for baricitinib available, what challenges still remain for the alopecia areata treatment and what other agents are on the horizon?